 therapi renal cell carcinoma lymphokine-activ killer cell phase II experi hybrid bolu continu infus regimen forty-seven patient metastat unresect renal cell carcinoma lymphokine-activ killer lak -cell therapi hybrid regimen intraven bolu u/kg cetu corp emeryvil CA hour day prime phase continu infus day second treatment period vitro-gener lak cell select patient good perform statu PS PS PS nephrectomi patient low tumor burden respons rate low complet cr partial respons pr overal object respons rate toxic compar high-dos bolu regimen result dose schedul administr likelihood respons renal cell carcinoma